Lebrunet al. anti-muscle-specific tyrosine kinase (MuSK) antibodies. The medical course of MuSK antibody-positive MG individuals is characterized by a severe disease with severe bulbar symptoms, frequent exacerbations, and less favorable response to the first-line treatment (steroids, azathioprine, mycophenolate, intravenous immunoglobulin [IVIG], or plasmapheresis) as compared to AChR-positive individuals. The recent availability of rituximab offers raised hopes in the management of these individuals. We statement our encounter with six anti-MuSK antibody-positive MG individuals who have been refractory to the standard treatment and were later on responded well to rituximab. == Individuals and Methods == This prospective study was carried out at a tertiary care teaching hospital and referral center in Northern India. The details of individuals are given below inTable 1. An Institutional Ethics clearance was acquired for the study (INT/IEC/2017/1357) (Research No.NK/3899/res/640). Rituximab was given in standard doses of 375 mg/m2weekly for 4 weeks. At follow-up, the next cycle of rituximab was given according to CD19 cell counts done at regular monthly intervals starting from 6 months. Repeat cycles of rituximab were given once CD19 cell counts were >1% and serum IgG levels were normal. == Table 1. == Clinical details of individuals with muscle-specific tyrosine kinase antibody-positive myasthenia gravis CT=Computed tomography, AZA=Azathioprine, MMF=Mycophenolate, PLEX=Plasma exchange, IVIG=Intravenous immunoglobulin, Cyclo=Cyclophosphamide == Results: Case Series == == Ezatiostat hydrochloride Patient 1 == A 50-year-old gentleman, with no previous comorbidities, presented with difficulty in neck holding, double vision, and ptosis of 2 12 months duration. Repeated nerve activation (RNS) and neostigmine test were suggestive of MG. Anti-AChR was bad. The patient was started on steroids, pyridostigmine, and azathioprine. Contrast-enhanced computed tomography (CECT) scan of the chest was normal. He improved symptomatically but never had total remission. After 1 years, he had worsening of symptoms associated with difficulty in nibbling and swallowing, slurring of conversation, and breathing difficulty. A analysis of myasthenic problems was made, and the patient was given five cycles of plasma exchange with no improvement in symptoms. Anti-MuSK antibody was positive. He was started on intravenous (IV) rituximab (375 mg/m2) weekly for 4 weeks, and the symptoms gradually improved. After 2 weeks of initiation of treatment, the deep breathing difficulty resolved, and ptosis, diplopia, and neck holding improved after the next 2 months. Steroids and azathioprine were tapered and halted. He is doing well currently at Ezatiostat hydrochloride 24 months of follow-up after three cycles of rituximab and is planned for another cycle. == Patient 2 == A 23-year-old woman offered a with 9-month history of weakness in the neck and limb muscle tissue along with bilateral ptosis. RNS and neostigmine test were suggestive of MG. AChR antibodies were bad. With anticipating an impending problems, she was given IVIG inside a dosage of 2 g/kg. Her symptoms improved and she was discharged on steroids, mycophenolate, and pyridostigmine. Two months later, she started having swallowing difficulty for which she received another course of IVIG (2 g/kg) elsewhere. Mycophenolate and steroids were continued. Five months later on, she again experienced dysphagia and ptosis with progressive shortness of breath. She was given IVIG (2 g/kg) for the third time; mycophenolate was replaced by azathioprine. Anti-MuSK sent right now was positive and CECT chest was normal. Again 2 months later, she experienced ptosis, dysphagia, and hoarseness of voice. This time she was Ezatiostat hydrochloride given five cycles of plasma exchange with only slight improvement. In view of prolonged symptoms, rituximab (375 mgm2weekly for 4 weeks) was given. Her bulbar symptoms improved in 2 weeks, and she Rabbit Polyclonal to LRG1 started taking oral feeds. She is doing well and is in total remission at 18-month follow-up after completion of two cycles of rituximab. == Ezatiostat hydrochloride Patient 3 == A 49-year-old woman with MuSK-positive MG, diagnosed outside and treated with steroids, presented with fever, cough, and breathlessness for.
